Emcure Pharmaceuticals Complete Financial Statements

In FY2025, Emcure Pharmaceuticals (EMCURE) reported revenue ₹2,273 Cr, net profit ₹251 Cr and EPS ₹12.85, with a net profit margin of 11.0% and ROE of 5.4%. Full financial statements from FY2018 to FY2025 (8 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see EMCURE company profile.

8 Years of Data
2025 - 2018

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 11.04% 2025 data
EBITDA Margin 21.07% 2025 data
Operating Margin 21.00% 2025 data
Return on Assets 3.05% 2025 data
Return on Equity 5.41% 2025 data

Balance Sheet Ratios

Current Ratio 4.94 2025 data
Equity Ratio 56.38% 2025 data
Asset Turnover 0.28 2025 data

EMCURE Revenue, Net Profit & EBITDA — Year-on-Year Growth

EMCURE YoY (Sept 2024 vs Sept 2025) — revenue +11.5%, net profit +24.3%, EBITDA +14.9%, expenses +10.7%.

Revenue Growth
+11.5%
Year-over-Year
Net Profit Growth
+24.3%
Year-over-Year
EBITDA Growth
+14.9%
Year-over-Year
Expense Growth
+10.7%
Year-over-Year
Assets Growth
+5.5%
Year-over-Year
Equity Growth
+48.7%
Year-over-Year
Operating Cash Flow Growth
-22.3%
Year-over-Year
Investing Cash Flow Growth
+86.6%
Year-over-Year
Financing Cash Flow Growth
-396.3%
Year-over-Year

EMCURE Income Statement — Revenue, EBITDA & Net Profit

Emcure Pharmaceuticals revenue ₹2,273 Cr, EBITDA ₹479 Cr, net profit ₹251 Cr, EPS ₹12.85 (2025) — net profit margin 11.0%. Explore EMCURE true value to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Mar 2024 Jun 2024 Dec 2024 Sept 2023 Jun 2023 Dec 2023
Revenue 2,273 2,121 2,104 2,365 2,038 1,783 1,839 1,967 1,664 1,571 1,697
Expenses 1,794 1,724 1,687 1,909 1,621 1,460 1,479 1,608 1,337 1,261 1,381
EBITDA 479 397 417 456 417 323 360 359 327 311 316
Operating Profit Margin % 21.00% 19.00% 20.00% 19.00% 19.00% 18.00% 19.00% 18.00% 20.00% 19.00% 17.00%
Depreciation 105 97 100 105 97 91 94 97 70 67 84
Interest 33 39 27 38 46 66 59 32 59 52 61
Profit Before Tax 341 261 291 314 273 167 207 230 198 191 171
Tax 90 63 76 82 72 46 55 74 52 50 51
Net Profit 251 197 215 231 202 121 153 156 146 141 120
Earnings Per Share (₹) 12.85 9.97 10.92 12.16 10.23 6.36 7.95 8.12 7.70 7.21 6.27

EMCURE Balance Sheet — Assets, Liabilities & Shareholders' Equity

EMCURE total assets ₹8,233 Cr, total equity ₹4,642 Cr, total liabilities ₹ Cr (2025) — ROE 5.4%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020 2019 2018
ASSETS
Total Assets 8,233 7,806 6,673 6,064 6,807 6,004 5,644 5,247
Current Assets 4,556 4,260 3,836 3,424 3,718 2,703 2,453 2,335
Fixed Assets 3,197 3,125 2,147 2,044 2,188 2,382 2,247 2,049
Capital Work in Progress 177 159 411 320 302 485 581 531
Investments 95 318 25 25 0 0 0 0
Other Assets 4,763 4,204 4,089 3,674 4,318 3,137 2,817 2,667
LIABILITIES
Total Liabilities
Current Liabilities 923 1,474 1,004 985 1,031 1,100 1,201 1,157
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 4,642 3,122 2,650 2,114 2,368 1,984 1,900 1,755
Share Capital 190 181 181 181 181 181 181 181
Reserves & Surplus 4,257 2,771 2,320 1,807 2,092 1,731 1,654 1,520

EMCURE Cash Flow Statement — Operating, Investing & Financing

Emcure Pharmaceuticals operating cash flow ₹852 Cr, investing ₹-96 Cr, financing ₹-814 Cr, net cash flow ₹-58 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019
Operating Activities 852 1,097 747 768 704 500 444
Investing Activities -96 -715 -468 -575 -257 -168 -409
Financing Activities -814 -164 -145 -152 -189 -301 -735
Net Cash Flow -58 219 134 42 259 32 -700